Ventilation inhomogeneity in infants with recurrent wheezing

Thorax. 2018 Oct;73(10):936-941. doi: 10.1136/thoraxjnl-2017-211351. Epub 2018 Jun 15.

Abstract

Background: The care of infants with recurrent wheezing relies largely on clinical assessment. The lung clearance index (LCI), a measure of ventilation inhomogeneity, is a sensitive marker of early airway disease in children with cystic fibrosis, but its utility has not been explored in infants with recurrent wheezing.

Objective: To assess ventilation inhomogeneity using LCI among infants with a history of recurrent wheezing compared with healthy controls.

Methods: This is a case-control study, including 37 infants with recurrent wheezing recruited from outpatient clinics, and 113 healthy infants from a longitudinal birth cohort, the Canadian Healthy Infant Longitudinal Development study. All infants, at a time of clinical stability, underwent functional assessment including multiple breath washout, forced expiratory flows and body plethysmography.

Results: LCI z-score values among infants with recurrent wheeze were 0.84 units (95% CI 0.41 to 1.26) higher than healthy infants (mean (95% CI): 0.26 (-0.11 to 0.63) vs -0.58 (-0.79 to 0.36), p<0.001)). Nineteen percent of recurrently wheezing infants had LCI values that were above the upper limit of normal (>1.64 z-scores). Elevated exhaled nitric oxide, but not symptoms, was associated with abnormal LCI values in infants with recurrent wheeze (p=0.05).

Conclusions: Ventilation inhomogeneity is present in clinically stable infants with recurrent wheezing.

Keywords: asthma; lung physiology; paediatric asthma; respiratory measurement.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Asthma / physiopathology*
  • Canada
  • Case-Control Studies
  • Child, Preschool
  • Female
  • Humans
  • Infant
  • Longitudinal Studies
  • Lung / physiopathology*
  • Male
  • Nitric Oxide / analysis
  • Plethysmography / methods
  • Respiratory Function Tests / methods*
  • Respiratory Sounds / physiopathology*

Substances

  • Nitric Oxide

Grants and funding